Max Robotics — Global Service Robot Directory + US Certification

About

Masaki Ohi is a leading surgical oncologist whose work is reshaping the landscape of gastric cancer treatment. His primary research focuses on the comparative effectiveness of robotic versus laparoscopic gastrectomy, with a specific emphasis on reducing postoperative complications. Ohi’s most impactful contribution is his landmark 2021 study, which demonstrated that robotic gastrectomy (RG) is associated with a significantly lower incidence of severe intra-abdominal infectious complications, such as pancreatic fistula and abscess, compared to the laparoscopic approach. Garnering over 223 citations, this work has become a cornerstone reference in the field. He further solidified these findings with a subsequent randomized clinical trial in 2023, underscoring the urgent need for prospective data. Beyond comparative trials, Ohi has pioneered technical innovations, including the Billroth-I reconstruction with overlap anastomosis using an EndoWrist linear stapler, a refined technique designed to enhance safety and precision after robotic distal gastrectomy. Through his rigorous clinical trials and technical advancements, Ohi is providing the high-level evidence needed to guide surgical decision-making and improve outcomes for patients with gastric cancer.